CytoDyn (STU:296) ROE % Adjusted to Book Value : 0.00% (As of Feb. 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytoDyn ROE % Adjusted to Book Value?

CytoDyn's ROE % for the quarter that ended in Feb. 2025 was 0.00%. CytoDyn's PB Ratio for the quarter that ended in Feb. 2025 was N/A. CytoDyn's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2025 was N/A.

CytoDyn ROE % Adjusted to Book Value Historical Data

The historical data trend for CytoDyn's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn ROE % Adjusted to Book Value Chart

CytoDyn Annual Data

Trend

May15

May16

May17

May18

May19

May20

May21

May22

May23

May24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

CytoDyn Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	Negative Equity	-	-

Competitive Comparison of CytoDyn's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CytoDyn's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CytoDyn's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

CytoDyn ROE % Adjusted to Book Value Calculation

CytoDyn's ROE % Adjusted to Book Value for the fiscal year that ended in May. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

CytoDyn's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

CytoDyn ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CytoDyn's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CYDY:USA

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines